Heron Therapeutics Inc. (HRTX)

Trade HRTX now with
10/4/2019 12:03:19 AM Heron Therapeutics Announces Pricing Of Public Offering Of 8.57 Mln Shares At $17.50/Shr
10/3/2019 4:07:20 PM Heron Therapeutics Announces Proposed Public Offering Of Common Stock
10/2/2019 7:49:08 AM Heron Reports Positive Topline Results From Phase 3b Clinical Study Of HTX-011 In Total Knee Arthroplasty
10/1/2019 4:12:56 PM Heron Therapeutics Appoints Stephen Davis To Board Of Directors
10/1/2019 8:32:58 AM Heron Resubmits New Drug Application To FDA For HTX-011 For Management Of Postoperative Pain
8/20/2019 8:32:05 AM Heron Therapeutics Announces Publication Of Results From EPOCH 2; Meets End Points
8/5/2019 8:57:33 AM  Heron Therapeutics Q2 Loss/shr $0.63 Vs. Loss/shr $0.54 Prior Year
5/21/2019 9:15:13 AM Heron Reports Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy
5/9/2019 8:35:39 AM Heron Therapeutics Q1 Net Loss $63.0 Mln Or $0.80/Shr Vs Loss $52.3 Mln Or $0.81/Shr Last Year
4/1/2019 8:38:36 AM Heron Announces EMA Validation Of Marketing Authorisation Application For HTX-011 For Postoperative Pain Management
2/22/2019 8:35:59 AM Heron Therapeutics Q4 Net Loss $49.6 Mln Or $0.63/shr Vs Net Loss $62.5 Mln Or $1.09/shr Prior Year
12/31/2018 8:31:35 AM Heron Therapeutics Says FDA Grants Priority Review Designation For NDA For HTX-011
8/8/2018 8:41:37 AM Heron Therapeutics Q2 Net Loss $38.7 Mln Or $0.54/Shr Vs Loss $42.8 Mln Or $0.80/Shr Last Year
6/25/2018 10:04:24 PM Heron Therapeutics Announces Pricing Of Underwritten Public Offering Of About $200 Mln Of Shares